Founded in July 2008, Adaptimmune is focused on the use of T cell therapy to treat cancer and infectious disease.  It aims to utilise the body’s own machinery – the T cell – to target and destroy cancerous or infected cells.  Adaptimmune’s mission is to take so-called “adoptive T cell therapy” to the next level by leveraging its expertise in engineering high affinity T cell receptor proteins (TCRs) as a means of “supercharging” the strength of patient T cell responses.  Adaptimmune holds an exclusive licence to the use of Immunocore Ltd’s (formerly Avidex/MediGene) unique T cell receptor engineering technology for adoptive T cell therapy.  It is aiming to exploit this unique capability in the development of targeted T cell therapy in cancer and infectious disease.

Backed by private investors and located alongside Immunocore Ltd in its Oxford facilities, Adaptimmune operates a virtual business model with a small, focused management team and strong academic collaborations for the conduct of research, preclinical and clinical studies in HIV and cancer.